|本期目录/Table of Contents|

[1]马晓惠,单艳华,李小霞,等.ω-3鱼油脂肪乳剂对重症胰腺炎患者腹内高压及肠黏膜功能的影响[J].天津医科大学学报,2023,29(01):73-77.
 MA Xiao-hui,SHAN Yan-hua,LI Xiao-xia,et al.Effects of omega-3 fish oil lipid emulsion on intra-abdominal hypertension and intestinal mucosal function in patients with severe pancreatitis[J].Journal of Tianjin Medical University,2023,29(01):73-77.
点击复制

ω-3鱼油脂肪乳剂对重症胰腺炎患者腹内高压及肠黏膜功能的影响(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
29卷
期数:
2023年01期
页码:
73-77
栏目:
临床医学
出版日期:
2023-01-20

文章信息/Info

Title:
Effects of omega-3 fish oil lipid emulsion on intra-abdominal hypertension and intestinal mucosal function in patients with severe pancreatitis
文章编号:
1006-8147(2023)01-0073-05
作者:
马晓惠单艳华李小霞王喜梅
(驻马店市中心医院重症医学科,驻马店 463000)
Author(s):
MA Xiao-huiSHAN Yan-huaLI Xiao-xiaWANG Xi-mei
(Department of Critical Medicine,Zhumadian Central Hospital,Zhumadian 463000,China)
关键词:
ω-3鱼油脂肪乳剂重症胰腺炎腹内高压肠黏膜功能
Keywords:
somega-3 fish oil fat emulsionsevere pancreatitisintra-abdominal hypertensionintestinal mucosal function
分类号:
R781.4
DOI:
-
文献标志码:
A
摘要:
目的:探讨ω-3鱼油脂肪乳剂对重症胰腺炎患者腹内高压及肠黏膜功能的影响。方法:选择驻马店市中心医院重症医学科收治的136例重症胰腺炎患者作为研究对象,进行前瞻性研究,并按照随机数字表法分为对照组和观察组,各68例。其中对照组给予常规治疗法进行治疗,观察组在上述治疗的基础上外加ω-3鱼油脂肪乳剂进行治疗。观察两组患者治疗后病情缓解时间变化,比较两组患者治疗前后肠黏膜功能指标、趋化因子及腹内压水平变化,分析两组患者治疗效果差异。结果:观察组腹痛缓解时间、腹胀缓解时间、肠鸣音恢复时间以及肛门首次排便时间等病情症状明显改善(均P<0.05)。与治疗前相比,两组治疗后的血清肠型脂肪酸结合蛋白(I-FABP)、二胺氧化酶(DAO)、D-乳酸、中性粒细胞趋化因子(CINC)、FKN、单核细胞趋化因子蛋白-1(MCP-1)及乳果糖/甘露醇(L/M)、腹内压水平明显低于对照组,血清三叶因子(ITF)、乳脂球表皮生长因子8(MFG-E8)明显降低,且观察组改善更显著(均P<0.05)。观察组患者治疗有效率为94.12%,明显高于对照组的76.47%(P<0.05)。结论:ω-3鱼油脂肪乳剂治疗重症胰腺炎患者,可以有效缓解其临床症状,改善腹内高压及肠黏膜功能,增强疗效,具有一定临床参考价值。
Abstract:
Objective: To explore the effect of omega-3 fish oil fat emulsion on intra-abdominal hypertension and intestinal mucosal function in patients with severe acute pancreatitis. Methods:A total of 136 patients with severe pancreatitis admitted to the Department of Critical Care Medicine of Zhumadian Central Hospital were selected as the research objects for prospective study,and they were divided into the control group and the observation group according to the random number table method,with 68 cases in each group. The control group was treated with conventional therapy,and the observation group was additionally treated with omega-3 fish oil fat emulsion on the basis of the above treatment. The changes in the remission time of patients of the two groups after treatment were observed,the changes of intestinal mucosal function indexes,chemokines and intra-abdominal pressure levels were compared between the two groups before and after treatment,and the differences in the treatment effects of the two groups were analyzed. Results:The symptoms of abdominal pain relief,abdominal distension relief time,bowel sound recovery time and anal first defecation time were significantly proved in the observation group,and the difference was statistically significant(all P<0.05).Compared with before treatment,the levels of serum intestinal fatty acid binding protein(I-FABP),diamine oxidase(DAO),D-lactic acid,neutrophil chemokine(CINC),FKN,monocyte chemokine protein-1 (MCP-1),lactulose/mannitol (L/M) and intra-abdominal pressure of the two groups were significantly lower than those of the control group,serum trefoil factor(ITF) and lactoglobular epidermal growth factor 8(MFG-E8) were significantly higher than those of the control group,and the above indicators were significantly improved in the observation group(all P<0.05).The effective rate of treatment in the observation group was 94.12%,which was significantly higher than that in the control group(76.47%). The difference was statistically significant(P<0.05). Conclusion:Omega-3 fish oil fat emulsion in the treatment of patients with severe pancreatitis can effectively alleviate its clinical symptoms,improve intra-abdominal hypertension and intestinal mucosal function,enhance the curative effect,and have certain clinical reference value.

参考文献/References:

[1] FORNER A,REIGM,BRUIX J. Hepatocellular carcinoma[J]. Lancet,2018,391(10127):1301-1314.
[2] COLQUHOUN S D. Hepatocellular carcinoma:the current role of surgical intervention[J]. Crit Rev Oncog,2016,21(1):93-103.
[3] 刘秀红,赵一鸣,赵晓飞,等. 肝细胞癌诊断与治疗研究进展[J].中国肝脏病杂志(电子版),2017,9(02):20-25.
[4] 罗希,张雅敏.糖尿病与肝细胞癌的相关研究进展[J].中华肝胆外科杂志,2020,26(09):717-720.
[5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019 年版)[J].中国实用外科杂志,2020,40(2):121-138.
[6] 方靓,王文平,陈悦,等.肝小血管瘤超声造影表现及其诊断[J].复旦学报(医学版),2021,48(5):618-623.
[7] 何垚,杨龙,袁建军,等.原发性肝癌超声造影血流灌注参数与肿瘤分化程度及微血管生成的关系[J].中国医学影像技术,2021, 37(8):1177-1181.
[8] 李宁. 超声造影在腹腔镜肾部分切除术中的应用研究[J]. 天津医科大学学报,2019,25(6):631-633.
[9] VILLANUEV A A. Hepatocellular carcinoma[J].New Engl J Med,2019,380(15):1450-1462.
[10] KANG C M,CHOI G H,KIM D H,et al. Revisiting the role of nonanatomic resection of small([11] TAN Y,ZHANG W,JIANG L,et al. Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma:a systemic review and meta-analysis[J]. PLoS One,2017,12(10):e0186930.
[12] 尹新民,朱鹏,张万广,等. 腹腔镜肝切除术专家共识(2013 版)[J]. 中国肿瘤临床,2013,40(6):303-307.
[13] 王新团,张引涛. 腹腔镜精准肝切除治疗原发性肝癌的疗效观察[J]. 中华普外科手术学杂志:电子版,2018,12(5):379-381.
[14] JIANG J,CHEN Y,ZHOU Y,et al. Clear cell renal cell carcinoma:contrast-enhanced ultrasound features relation to tumor size[J]. Eur J Radiol,2010,73(1):162-165.
[15] 张艳辉,杨庆,崔巍,等. 不同亚型肾细胞癌的微血管密度与临床病理因素的关系[J]. 中华肿瘤杂志,2010,32(2):117-122.
[16] 杨丽,张祖艳,柴大敏,等. 周围型肺癌CT征象与PCNA和Bcl-2及Caspase-3蛋白表达关联研究[J]. 中华肿瘤防治杂志,2020, 27(8):605-611.
[17] 李辰,闻愚,张天锋,等. 胃黏膜病变组织Hp感染及c-myc和PCNA表达及其临床意义[J]. 中华医院感染学杂志,2021,31(8):1140-1144.
[18] ROSSB,DORLEANS J P,GIAID A. Potential role of endothelin-1 in pulmonary fibrosis:from the bench to theclinic[J]. Am J Respir Cell Mol Biol,2010,42(1):16-20.
[19] 潘琼,谷见法,刘松格,等. miR-133过表达对结肠癌细胞SW480凋亡、增殖和裸鼠成瘤的影响[J].天津医科大学学报,2021, 27(5):472-476.
[20] MARACLE C X,JEUCKEN KCM,HELDER B,et al. Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis[J]. Oncotarget,2018,9(47):28445-28455.
[21] TZARTZEVA K,OBI J,RICH N E,et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis:a meta-analysis[J]. Gastroenterology,2018, 154(6):1706-1718.
[22] 龙运敏,张卫. 超声技术在肝细胞癌诊疗中的研究进展[J].中国癌症防治杂志,2022,14(2):224-228.
[23] MATSUDA Y,YABUUCHI I. Hepatic tumors:US contrast enhancement with CO2 microbubbles[J]. Radiology,1986,161(3):701-705.
[24] SCHWARZE V,MARSCHNER C,VOLCKERS W,et al. The diagnostic performance of contrast-enhanced ultrasound(CEUS) for evaluating hepatocellular carcinoma(HCC) juxtaposed to MRI findings;a retrospective single-center analysis of 292 patients[J]. Clin Hemorheol Microcirc,2020,76(2):155-160.
[25] KIM T H,YOON J H,LEE J M. Emerging role of hepatobiliary magnetic resonance contrast media and contrast-enhanced ultrasound for noninvasive diagnosis of hepatocellular carcinoma:emphasis on recent updates in major guidelines[J]. Korean J Radiol,2019,20(6):863-879.

相似文献/References:

备注/Memo

备注/Memo:
作者简介:马晓惠(1981-),女,主治医师,学士,研究方向:重症医学;E-mail:yangcang14@126.com。
更新日期/Last Update: 2023-02-01